CS198236B2 - Method of producing n-/5-tetrazolyl/-4-oxo-4h-pyrimido/2,1-b/benzothiazole-3-carboxamides - Google Patents
Method of producing n-/5-tetrazolyl/-4-oxo-4h-pyrimido/2,1-b/benzothiazole-3-carboxamides Download PDFInfo
- Publication number
- CS198236B2 CS198236B2 CS772079A CS207977A CS198236B2 CS 198236 B2 CS198236 B2 CS 198236B2 CS 772079 A CS772079 A CS 772079A CS 207977 A CS207977 A CS 207977A CS 198236 B2 CS198236 B2 CS 198236B2
- Authority
- CS
- Czechoslovakia
- Prior art keywords
- group
- oxo
- benzothiazole
- pyrimido
- formula
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 18
- 150000001875 compounds Chemical class 0.000 claims description 33
- ULRPISSMEBPJLN-UHFFFAOYSA-N 2h-tetrazol-5-amine Chemical compound NC1=NN=NN1 ULRPISSMEBPJLN-UHFFFAOYSA-N 0.000 claims description 22
- -1 5-tetrazolyl Chemical group 0.000 claims description 21
- 150000003839 salts Chemical class 0.000 claims description 14
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims description 12
- 229910052739 hydrogen Inorganic materials 0.000 claims description 9
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 8
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 6
- 239000000460 chlorine Substances 0.000 claims description 6
- 238000002360 preparation method Methods 0.000 claims description 6
- 230000008569 process Effects 0.000 claims description 6
- SZXLBDVCHABEGD-UHFFFAOYSA-N 2h-1,3-benzothiazole-3-carboxamide Chemical class C1=CC=C2N(C(=O)N)CSC2=C1 SZXLBDVCHABEGD-UHFFFAOYSA-N 0.000 claims description 5
- 229910052801 chlorine Inorganic materials 0.000 claims description 5
- 238000011282 treatment Methods 0.000 claims description 5
- 229910052799 carbon Inorganic materials 0.000 claims description 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 4
- 125000002816 methylsulfanyl group Chemical group [H]C([H])([H])S[*] 0.000 claims description 4
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 3
- 229910052731 fluorine Inorganic materials 0.000 claims description 3
- 125000001153 fluoro group Chemical group F* 0.000 claims description 3
- 239000001257 hydrogen Substances 0.000 claims description 3
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 3
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims description 2
- 125000006274 (C1-C3)alkoxy group Chemical group 0.000 claims description 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 2
- KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 claims description 2
- 230000010933 acylation Effects 0.000 claims description 2
- 238000005917 acylation reaction Methods 0.000 claims description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical group BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 2
- 229910052794 bromium Inorganic materials 0.000 claims description 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 2
- GNOIPBMMFNIUFM-UHFFFAOYSA-N hexamethylphosphoric triamide Chemical compound CN(C)P(=O)(N(C)C)N(C)C GNOIPBMMFNIUFM-UHFFFAOYSA-N 0.000 claims description 2
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims description 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 2
- 101100294106 Caenorhabditis elegans nhr-3 gene Proteins 0.000 claims 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 1
- 125000003277 amino group Chemical group 0.000 claims 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 1
- 239000003880 polar aprotic solvent Substances 0.000 claims 1
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 48
- 239000000203 mixture Substances 0.000 description 20
- 239000000047 product Substances 0.000 description 19
- 239000000243 solution Substances 0.000 description 14
- 238000006243 chemical reaction Methods 0.000 description 13
- 239000000725 suspension Substances 0.000 description 13
- 239000004480 active ingredient Substances 0.000 description 12
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 12
- 239000000126 substance Substances 0.000 description 12
- 208000003455 anaphylaxis Diseases 0.000 description 11
- 238000010438 heat treatment Methods 0.000 description 11
- 206010002198 Anaphylactic reaction Diseases 0.000 description 10
- PIINGSXUWUVNKU-UHFFFAOYSA-N 4-oxopyrimido[2,1-b][1,3]benzothiazole-3-carboxylic acid Chemical class S1C2=CC=CC=C2N2C1=NC=C(C(=O)O)C2=O PIINGSXUWUVNKU-UHFFFAOYSA-N 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 9
- 238000002844 melting Methods 0.000 description 9
- 230000008018 melting Effects 0.000 description 9
- 206010020751 Hypersensitivity Diseases 0.000 description 8
- 239000011541 reaction mixture Substances 0.000 description 8
- 229940027941 immunoglobulin g Drugs 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
- 208000026935 allergic disease Diseases 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 238000003556 assay Methods 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
- RZZPDXZPRHQOCG-OJAKKHQRSA-O CDP-choline(1+) Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OCC[N+](C)(C)C)O[C@H]1N1C(=O)N=C(N)C=C1 RZZPDXZPRHQOCG-OJAKKHQRSA-O 0.000 description 4
- 108060003951 Immunoglobulin Proteins 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- 230000000172 allergic effect Effects 0.000 description 4
- 230000003266 anti-allergic effect Effects 0.000 description 4
- 239000000427 antigen Substances 0.000 description 4
- 102000036639 antigens Human genes 0.000 description 4
- 108091007433 antigens Proteins 0.000 description 4
- 208000006673 asthma Diseases 0.000 description 4
- 208000010668 atopic eczema Diseases 0.000 description 4
- VLARUOGDXDTHEH-UHFFFAOYSA-L disodium cromoglycate Chemical compound [Na+].[Na+].O1C(C([O-])=O)=CC(=O)C2=C1C=CC=C2OCC(O)COC1=CC=CC2=C1C(=O)C=C(C([O-])=O)O2 VLARUOGDXDTHEH-UHFFFAOYSA-L 0.000 description 4
- JBFYUZGYRGXSFL-UHFFFAOYSA-N imidazolide Chemical compound C1=C[N-]C=N1 JBFYUZGYRGXSFL-UHFFFAOYSA-N 0.000 description 4
- 102000018358 immunoglobulin Human genes 0.000 description 4
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 4
- 239000000376 reactant Substances 0.000 description 4
- 230000035484 reaction time Effects 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- IVRZHCPGPPBIHN-UHFFFAOYSA-N 4-oxo-n-(2h-tetrazol-5-yl)pyrimido[2,1-b][1,3]benzothiazole-3-carboxamide Chemical class C=1N=C2SC3=CC=CC=C3N2C(=O)C=1C(=O)NC1=NN=NN1 IVRZHCPGPPBIHN-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- 206010039085 Rhinitis allergic Diseases 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 201000010105 allergic rhinitis Diseases 0.000 description 3
- 230000007815 allergy Effects 0.000 description 3
- 230000036783 anaphylactic response Effects 0.000 description 3
- 150000008064 anhydrides Chemical class 0.000 description 3
- 239000000043 antiallergic agent Substances 0.000 description 3
- 239000012736 aqueous medium Substances 0.000 description 3
- 229940124630 bronchodilator Drugs 0.000 description 3
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 229960000265 cromoglicic acid Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 239000000975 dye Substances 0.000 description 3
- 239000012442 inert solvent Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000011343 solid material Substances 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- BPXGVDLTYDVZDZ-UHFFFAOYSA-N 8-methoxy-4-oxopyrimido[2,1-b][1,3]benzothiazole-3-carboxylic acid Chemical compound C1=C(C(O)=O)C(=O)N2C3=CC=C(OC)C=C3SC2=N1 BPXGVDLTYDVZDZ-UHFFFAOYSA-N 0.000 description 2
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 description 2
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 206010010904 Convulsion Diseases 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 108010058846 Ovalbumin Proteins 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 150000004703 alkoxides Chemical class 0.000 description 2
- 201000009961 allergic asthma Diseases 0.000 description 2
- 150000001412 amines Chemical group 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- 239000007900 aqueous suspension Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000000168 bronchodilator agent Substances 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- PAFZNILMFXTMIY-UHFFFAOYSA-N cyclohexylamine Chemical compound NC1CCCCC1 PAFZNILMFXTMIY-UHFFFAOYSA-N 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- RIFGWPKJUGCATF-UHFFFAOYSA-N ethyl chloroformate Chemical compound CCOC(Cl)=O RIFGWPKJUGCATF-UHFFFAOYSA-N 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 125000005842 heteroatom Chemical group 0.000 description 2
- 150000004678 hydrides Chemical class 0.000 description 2
- 230000000521 hyperimmunizing effect Effects 0.000 description 2
- 230000002163 immunogen Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 239000000543 intermediate Substances 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- RZXMPPFPUUCRFN-UHFFFAOYSA-N p-toluidine Chemical compound CC1=CC=C(N)C=C1 RZXMPPFPUUCRFN-UHFFFAOYSA-N 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- WGYKZJWCGVVSQN-UHFFFAOYSA-N propylamine Chemical compound CCCN WGYKZJWCGVVSQN-UHFFFAOYSA-N 0.000 description 2
- 238000001953 recrystallisation Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 1
- AVFZOVWCLRSYKC-UHFFFAOYSA-N 1-methylpyrrolidine Chemical compound CN1CCCC1 AVFZOVWCLRSYKC-UHFFFAOYSA-N 0.000 description 1
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 1
- CFMZSMGAMPBRBE-UHFFFAOYSA-N 2-hydroxyisoindole-1,3-dione Chemical compound C1=CC=C2C(=O)N(O)C(=O)C2=C1 CFMZSMGAMPBRBE-UHFFFAOYSA-N 0.000 description 1
- CSDQQAQKBAQLLE-UHFFFAOYSA-N 4-(4-chlorophenyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine Chemical compound C1=CC(Cl)=CC=C1C1C(C=CS2)=C2CCN1 CSDQQAQKBAQLLE-UHFFFAOYSA-N 0.000 description 1
- BTOJSYRZQZOMOK-UHFFFAOYSA-N 4-chloro-7-(4-methylphenyl)sulfonylpyrrolo[2,3-d]pyrimidine Chemical compound C1=CC(C)=CC=C1S(=O)(=O)N1C2=NC=NC(Cl)=C2C=C1 BTOJSYRZQZOMOK-UHFFFAOYSA-N 0.000 description 1
- AXBVSRMHOPMXBA-UHFFFAOYSA-N 4-nitrothiophenol Chemical compound [O-][N+](=O)C1=CC=C(S)C=C1 AXBVSRMHOPMXBA-UHFFFAOYSA-N 0.000 description 1
- RWVLSUFUYXWYKA-UHFFFAOYSA-N 4h-pyrimido[2,1-b][1,3]benzothiazole Chemical compound C1=CC=C2N3CC=CN=C3SC2=C1 RWVLSUFUYXWYKA-UHFFFAOYSA-N 0.000 description 1
- URZZJXMXBRJPCF-UHFFFAOYSA-N 7,8-diethoxy-4-oxo-n-(2h-tetrazol-5-yl)pyrimido[2,1-b][1,3]benzothiazole-3-carboxamide Chemical compound O=C1N2C=3C=C(OCC)C(OCC)=CC=3SC2=NC=C1C(=O)NC1=NN=NN1 URZZJXMXBRJPCF-UHFFFAOYSA-N 0.000 description 1
- OPZWXOQCGAIDCA-UHFFFAOYSA-N 7,8-dimethoxy-4-oxo-n-(2h-tetrazol-5-yl)pyrimido[2,1-b][1,3]benzothiazole-3-carboxamide Chemical compound O=C1N2C=3C=C(OC)C(OC)=CC=3SC2=NC=C1C(=O)NC=1N=NNN=1 OPZWXOQCGAIDCA-UHFFFAOYSA-N 0.000 description 1
- ILENOSUAEMVKMM-UHFFFAOYSA-N 7,8-dimethyl-4-oxo-n-(2h-tetrazol-5-yl)pyrimido[2,1-b][1,3]benzothiazole-3-carboxamide Chemical compound O=C1N2C=3C=C(C)C(C)=CC=3SC2=NC=C1C(=O)NC=1N=NNN=1 ILENOSUAEMVKMM-UHFFFAOYSA-N 0.000 description 1
- IWTGCYDFFCOUOE-UHFFFAOYSA-N 8-fluoro-4-oxopyrimido[2,1-b][1,3]benzothiazole-3-carboxylic acid Chemical compound C(=O)(O)C1=CN=C2SC3=C(N2C1=O)C=CC(=C3)F IWTGCYDFFCOUOE-UHFFFAOYSA-N 0.000 description 1
- KCJPPTGLAHROBR-UHFFFAOYSA-N 8-methyl-4-oxo-N-(2H-tetrazol-5-yl)pyrimido[2,1-b][1,3]benzothiazole-3-carboxamide Chemical compound N1N=NN=C1NC(=O)C1=CN=C2SC3=C(N2C1=O)C=CC(=C3)C KCJPPTGLAHROBR-UHFFFAOYSA-N 0.000 description 1
- DHXKERCISWENOV-UHFFFAOYSA-N 8-methyl-4-oxopyrimido[2,1-b][1,3]benzothiazole-3-carboxylic acid Chemical compound C1=C(C(O)=O)C(=O)N2C3=CC=C(C)C=C3SC2=N1 DHXKERCISWENOV-UHFFFAOYSA-N 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- 206010066091 Bronchial Hyperreactivity Diseases 0.000 description 1
- 206010006482 Bronchospasm Diseases 0.000 description 1
- COXVTLYNGOIATD-HVMBLDELSA-N CC1=C(C=CC(=C1)C1=CC(C)=C(C=C1)\N=N\C1=C(O)C2=C(N)C(=CC(=C2C=C1)S(O)(=O)=O)S(O)(=O)=O)\N=N\C1=CC=C2C(=CC(=C(N)C2=C1O)S(O)(=O)=O)S(O)(=O)=O Chemical compound CC1=C(C=CC(=C1)C1=CC(C)=C(C=C1)\N=N\C1=C(O)C2=C(N)C(=CC(=C2C=C1)S(O)(=O)=O)S(O)(=O)=O)\N=N\C1=CC=C2C(=CC(=C(N)C2=C1O)S(O)(=O)=O)S(O)(=O)=O COXVTLYNGOIATD-HVMBLDELSA-N 0.000 description 1
- 101100516554 Caenorhabditis elegans nhr-5 gene Proteins 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- WFZKRNIMSVDNBU-UHFFFAOYSA-N Creatinine sulfate mixture with serotonin Chemical compound [O-]S([O-])(=O)=O.C[NH+]1CC(=O)N=C1N.C1=C(O)C=C2C(CC[NH3+])=CNC2=C1 WFZKRNIMSVDNBU-UHFFFAOYSA-N 0.000 description 1
- 239000004338 Dichlorodifluoromethane Substances 0.000 description 1
- XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical compound C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 1
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000004705 High-molecular-weight polyethylene Substances 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 238000004566 IR spectroscopy Methods 0.000 description 1
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 1
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 1
- AFBPFSWMIHJQDM-UHFFFAOYSA-N N-methyl-N-phenylamine Natural products CNC1=CC=CC=C1 AFBPFSWMIHJQDM-UHFFFAOYSA-N 0.000 description 1
- AHVYPIQETPWLSZ-UHFFFAOYSA-N N-methyl-pyrrolidine Natural products CN1CC=CC1 AHVYPIQETPWLSZ-UHFFFAOYSA-N 0.000 description 1
- 150000007930 O-acyl isoureas Chemical class 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 208000037656 Respiratory Sounds Diseases 0.000 description 1
- 244000000231 Sesamum indicum Species 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 239000000150 Sympathomimetic Substances 0.000 description 1
- 206010045240 Type I hypersensitivity Diseases 0.000 description 1
- 206010047924 Wheezing Diseases 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 229910001860 alkaline earth metal hydroxide Inorganic materials 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- 239000000908 ammonium hydroxide Substances 0.000 description 1
- 230000002052 anaphylactic effect Effects 0.000 description 1
- 230000001088 anti-asthma Effects 0.000 description 1
- 230000001387 anti-histamine Effects 0.000 description 1
- 230000000794 anti-serotonin Effects 0.000 description 1
- 239000000924 antiasthmatic agent Substances 0.000 description 1
- 230000009830 antibody antigen interaction Effects 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 239000003420 antiserotonin agent Substances 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 239000000010 aprotic solvent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 150000007860 aryl ester derivatives Chemical class 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- RQPZNWPYLFFXCP-UHFFFAOYSA-L barium dihydroxide Chemical compound [OH-].[OH-].[Ba+2] RQPZNWPYLFFXCP-UHFFFAOYSA-L 0.000 description 1
- 229910001863 barium hydroxide Inorganic materials 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 239000001045 blue dye Substances 0.000 description 1
- 230000036427 bronchial hyperreactivity Effects 0.000 description 1
- 230000007885 bronchoconstriction Effects 0.000 description 1
- HQABUPZFAYXKJW-UHFFFAOYSA-N butan-1-amine Chemical compound CCCCN HQABUPZFAYXKJW-UHFFFAOYSA-N 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 230000004856 capillary permeability Effects 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- AFYPFACVUDMOHA-UHFFFAOYSA-N chlorotrifluoromethane Chemical compound FC(F)(F)Cl AFYPFACVUDMOHA-UHFFFAOYSA-N 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- IMZMKUWMOSJXDT-UHFFFAOYSA-N cromoglycic acid Chemical compound O1C(C(O)=O)=CC(=O)C2=C1C=CC=C2OCC(O)COC1=CC=CC2=C1C(=O)C=C(C(O)=O)O2 IMZMKUWMOSJXDT-UHFFFAOYSA-N 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 description 1
- 235000019404 dichlorodifluoromethane Nutrition 0.000 description 1
- GGSUCNLOZRCGPQ-UHFFFAOYSA-N diethylaniline Chemical compound CCN(CC)C1=CC=CC=C1 GGSUCNLOZRCGPQ-UHFFFAOYSA-N 0.000 description 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 229960003699 evans blue Drugs 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 229940046528 grass pollen Drugs 0.000 description 1
- PPZMYIBUHIPZOS-UHFFFAOYSA-N histamine dihydrochloride Chemical compound Cl.Cl.NCCC1=CN=CN1 PPZMYIBUHIPZOS-UHFFFAOYSA-N 0.000 description 1
- 229960004931 histamine dihydrochloride Drugs 0.000 description 1
- 150000004679 hydroxides Chemical class 0.000 description 1
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 150000002460 imidazoles Chemical class 0.000 description 1
- 150000007928 imidazolide derivatives Chemical class 0.000 description 1
- 230000000984 immunochemical effect Effects 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 208000030603 inherited susceptibility to asthma Diseases 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229940079865 intestinal antiinfectives imidazole derivative Drugs 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 210000002850 nasal mucosa Anatomy 0.000 description 1
- 239000006199 nebulizer Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- IOQPZZOEVPZRBK-UHFFFAOYSA-N octan-1-amine Chemical compound CCCCCCCCN IOQPZZOEVPZRBK-UHFFFAOYSA-N 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- BDAWXSQJJCIFIK-UHFFFAOYSA-N potassium methoxide Chemical compound [K+].[O-]C BDAWXSQJJCIFIK-UHFFFAOYSA-N 0.000 description 1
- 230000036515 potency Effects 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- WHMDPDGBKYUEMW-UHFFFAOYSA-N pyridine-2-thiol Chemical compound SC1=CC=CC=N1 WHMDPDGBKYUEMW-UHFFFAOYSA-N 0.000 description 1
- AAYNGPDGJLZBOU-UHFFFAOYSA-N pyrimido[2,1-b][1,3]benzothiazol-4-one Chemical class C1=CC=C2N3C(=O)C=CN=C3SC2=C1 AAYNGPDGJLZBOU-UHFFFAOYSA-N 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 206010039083 rhinitis Diseases 0.000 description 1
- 230000001932 seasonal effect Effects 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 150000004760 silicates Chemical class 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 206010041232 sneezing Diseases 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 239000012265 solid product Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- 229960000278 theophylline Drugs 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 229910000391 tricalcium phosphate Inorganic materials 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Valve-Gear Or Valve Arrangements (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US05/671,030 US4041163A (en) | 1976-03-29 | 1976-03-29 | N-(5-Tetrazolyl)-4-oxo-4H-pyrimido(2,1-b)benzothiazole-3-carboxamide antiallergy agents |
Publications (1)
Publication Number | Publication Date |
---|---|
CS198236B2 true CS198236B2 (en) | 1980-05-30 |
Family
ID=24692862
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CS772079A CS198236B2 (en) | 1976-03-29 | 1977-03-29 | Method of producing n-/5-tetrazolyl/-4-oxo-4h-pyrimido/2,1-b/benzothiazole-3-carboxamides |
Country Status (32)
Country | Link |
---|---|
US (1) | US4041163A (hu) |
JP (1) | JPS52118497A (hu) |
AR (1) | AR215886A1 (hu) |
AT (1) | AT355030B (hu) |
BE (1) | BE852485A (hu) |
BG (1) | BG27757A3 (hu) |
CA (1) | CA1079276A (hu) |
CH (1) | CH606019A5 (hu) |
CS (1) | CS198236B2 (hu) |
DD (1) | DD130247A5 (hu) |
DE (1) | DE2712079C3 (hu) |
DK (1) | DK146160C (hu) |
ES (1) | ES456944A1 (hu) |
FI (1) | FI60871C (hu) |
FR (1) | FR2346357A1 (hu) |
GB (2) | GB1560923A (hu) |
GR (1) | GR72695B (hu) |
HU (1) | HU173643B (hu) |
IE (1) | IE44031B1 (hu) |
IL (1) | IL51616A (hu) |
LU (1) | LU76970A1 (hu) |
NL (1) | NL166945C (hu) |
NO (1) | NO150044C (hu) |
NZ (1) | NZ183634A (hu) |
PH (1) | PH12757A (hu) |
PL (1) | PL103466B1 (hu) |
PT (1) | PT66321B (hu) |
RO (1) | RO71888A (hu) |
SE (1) | SE436570B (hu) |
SU (1) | SU784782A3 (hu) |
YU (1) | YU40669B (hu) |
ZA (1) | ZA771485B (hu) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2810863A1 (de) * | 1978-03-13 | 1979-09-27 | Boehringer Mannheim Gmbh | 1-oxo-1h-pyrimido eckige klammer auf 6,1-b eckige klammer zu benzthiazol-derivate und verfahren zu ihrer herstellung |
US4223031A (en) * | 1978-05-05 | 1980-09-16 | Mead Johnson & Company | Azolopyrimidinones |
US4491587A (en) * | 1978-05-05 | 1985-01-01 | Mead Johnson & Company | Tetrazole derivatives |
US4230707A (en) * | 1979-08-27 | 1980-10-28 | Warner-Lambert Company | Oxo-pyrido[1,2-a]thienopyrimidine compounds and methods for their production |
US4282360A (en) * | 1979-10-12 | 1981-08-04 | Hoffmann-La Roche Inc. | 7-Methylthio or methylsulfinyl-5-oxo-5H-thiazolo[2,3-b]quinazoline-2-carboxylic acid |
US4414388A (en) * | 1979-11-23 | 1983-11-08 | Pfizer Inc. | 1-Oxo-1H-thiazolo[3,2-a]pyrimidine-2-carboxamides |
DK151811C (da) * | 1979-11-23 | 1988-06-06 | Pfizer | Analogifremgangsmaade til fremstilling af n-(5-tetrazolyl)-1-oxo-1h-thiazolooe3,2-aaa-pyrimidin-2-carboxamider eller farmaceutisk acceptable kationsalte deraf samt 1-oxo-1h-thiazolooe3,2-aaapyrimidin-2-carboxylsyrer til anvendelse som udgangsmaterialer ved fremgangsmaaden |
US4423048A (en) * | 1979-11-23 | 1983-12-27 | Pfizer Inc. | Antiallergic and antiulcer 1-oxo-1H-thiazolo[3,2-a]pyrimidine-2-carboxamides and intermediates therefor |
US4535081A (en) * | 1979-11-23 | 1985-08-13 | Pfizer Inc. | Antiallergic and antiulcer 1-oxo-1H-thiazolo[3,2-a]pyrimidine-2-carboxamides and intermediates therefor |
US4443451A (en) * | 1981-07-15 | 1984-04-17 | Janssen Pharmaceutica N.V. | Bicyclic pyrimidin-5-one derivatives |
DE3208218A1 (de) * | 1982-03-06 | 1983-09-08 | Basf Ag, 6700 Ludwigshafen | Isoindolinfarbstoffe und deren verwendung |
GB8300728D0 (en) * | 1983-01-12 | 1983-02-16 | Erba Farmitalia | Substituted carboxy-thiazolo / 3 2 - a / pyrimidine derivatives |
JPS59163735U (ja) * | 1983-04-14 | 1984-11-02 | モリタ工業株式会社 | 家庭用風呂釜の給排気管装置 |
US4457932A (en) * | 1983-07-22 | 1984-07-03 | Bristol-Myers Company | Anti-ulcer agents |
US4762840A (en) * | 1984-02-13 | 1988-08-09 | Roussel Uclaf | Pyrimido[2,1-b]benzothiazoles having antiallergic activity |
US4879295A (en) * | 1986-09-27 | 1989-11-07 | Sawai Pharmaceutical Co., Ltd. | N-tetrazolyl thiazolecarboxyamide derivatives and their use |
US5063228A (en) * | 1990-05-31 | 1991-11-05 | A. H. Robbins Company, Incorporated | 4-(substitutedaminoethyl)-3,4-dihydro-2-alkylpyrimido[1,6-a]benzimidazol-1(2H)-ones as antiarrhythmic agents |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CH491944A (de) * | 1966-11-29 | 1970-06-15 | Ciba Geigy | Verfahren zur Herstellung von benzheterocyclischen Verbindungen |
-
1976
- 1976-03-29 US US05/671,030 patent/US4041163A/en not_active Expired - Lifetime
- 1976-12-07 IE IE2675/76A patent/IE44031B1/en unknown
-
1977
- 1977-02-11 GB GB5759/77A patent/GB1560923A/en not_active Expired
- 1977-03-01 SE SE7702272A patent/SE436570B/xx not_active IP Right Cessation
- 1977-03-07 IL IL51616A patent/IL51616A/xx unknown
- 1977-03-07 NO NO770782A patent/NO150044C/no unknown
- 1977-03-08 PH PH19544A patent/PH12757A/en unknown
- 1977-03-11 ZA ZA00771485A patent/ZA771485B/xx unknown
- 1977-03-14 CA CA273,886A patent/CA1079276A/en not_active Expired
- 1977-03-15 BE BE1008009A patent/BE852485A/xx not_active IP Right Cessation
- 1977-03-15 GR GR52996A patent/GR72695B/el unknown
- 1977-03-16 YU YU682/77A patent/YU40669B/xx unknown
- 1977-03-17 AT AT183877A patent/AT355030B/de not_active IP Right Cessation
- 1977-03-17 NL NL7702895.A patent/NL166945C/xx not_active IP Right Cessation
- 1977-03-17 FI FI770848A patent/FI60871C/fi not_active IP Right Cessation
- 1977-03-17 DK DK118277A patent/DK146160C/da not_active IP Right Cessation
- 1977-03-17 ES ES456944A patent/ES456944A1/es not_active Expired
- 1977-03-17 FR FR7708035A patent/FR2346357A1/fr active Granted
- 1977-03-17 CH CH337077A patent/CH606019A5/xx not_active IP Right Cessation
- 1977-03-17 DE DE2712079A patent/DE2712079C3/de not_active Expired
- 1977-03-17 NZ NZ183634A patent/NZ183634A/xx unknown
- 1977-03-18 JP JP3024077A patent/JPS52118497A/ja active Granted
- 1977-03-18 PT PT66321A patent/PT66321B/pt unknown
- 1977-03-18 LU LU76970A patent/LU76970A1/xx unknown
- 1977-03-22 BG BG035760A patent/BG27757A3/xx unknown
- 1977-03-23 AR AR266945A patent/AR215886A1/es active
- 1977-03-25 RO RO7789795A patent/RO71888A/ro unknown
- 1977-03-28 HU HU77PI569A patent/HU173643B/hu unknown
- 1977-03-28 SU SU772465654A patent/SU784782A3/ru active
- 1977-03-29 CS CS772079A patent/CS198236B2/cs unknown
- 1977-03-29 PL PL1977197000A patent/PL103466B1/pl unknown
- 1977-03-29 DD DD7700198118A patent/DD130247A5/xx unknown
- 1977-05-10 GB GB19542/77A patent/GB1516964A/en not_active Expired
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CS198236B2 (en) | Method of producing n-/5-tetrazolyl/-4-oxo-4h-pyrimido/2,1-b/benzothiazole-3-carboxamides | |
CA1098520A (en) | Optionally substituted 3-(1h-tetrazol-5-yl)-4h- pyrido¬1,2-a| pyrimidin-4-ones | |
US4006237A (en) | Tetrahydrocarbostyril derivatives for the prophylaxis of asthma, hayfever and rhinitis | |
NZ227125A (en) | Quinazoline derivatives and pharmaceutical compositions | |
IE47965B1 (en) | Cycloalkyltriazoles and process for obtaining same | |
NZ213013A (en) | 3-acylaminomethylimidazo(1,2-a)pyridine derivatives and pharmaceutical compositions | |
NZ199093A (en) | Imidazolyl-phenyl amidines | |
US4017625A (en) | Anti-allergic N-(5-tetrazolyl)-1-oxo-1H-6-alkoxypyrimido-[1,2-a]quinoline-2-carboxamides and intermediates therefor | |
Schwender et al. | 11-Oxo-11H-pyrido [2, 1-b] quinazoline-8-carboxylic acid, an orally active antiallergy agent | |
US4066766A (en) | 1-Oxo-6-substituted pyrimido [1,2-a]quinoline-2-carboxylic acids and derivatives thereof and their use as antiallergy agents | |
CA1117112A (en) | Pyrido¬1,2-a|pyrimidine-3-n-(1h-tetrazol-5-yl| carboxamide derivatives | |
US4031099A (en) | 4-Hydroxy-3-nitro-5,6,7,8 tetrahydro-carbostyrils | |
FI67706C (fi) | Foerfarande foer framstaellning av terapeutiskt anvaendbara n-5-tetrazolyl)-1-oxo-1h-tiazolo(3,2-a)pyrimidin-2-karboxyl atr | |
CS195731B2 (en) | Process for preparing n-/5-tetrazolyl/-1-oxo-1h-6-alkoxypyrimido/1,2-a/quinolin-2-carboxamides | |
CS207499B2 (en) | Method of making the heterocyclic aminopyrimidine compounds | |
PL166839B1 (en) | Method of obtaining novel 3-(mercaptoalkyl)-quinazolino-(1h,3h)-diones-2,4 | |
KR800001139B1 (ko) | N-(5-테트라졸릴)-4-옥소-4H-피리미도[2,1-b]벤조티아졸류의 제조방법 | |
KR790001315B1 (ko) | N-테트라졸릴-1-옥소-1H-6-(R₃-치환) 피리미도[1,2-a] 퀴놀린-2-카복스아미드류의 제조방법. | |
FI71158B (fi) | Foerfarande foer framstaellning av terapeutiskt anvaendbara 1-xo-1h-tiazolo/3,2-a/pyrimidin-2-karboxylsyror | |
US4085213A (en) | Tetrazolo[A]quinazol-5-ones antiallergy and antiulcer agents | |
US5306721A (en) | 3-(mercaptoalkyl)quinazoline | |
US4141979A (en) | Tetrazolo[a]quinazol-5-ones antiallergy and antiulcer agents | |
US3973020A (en) | 3-(2-Pyridinyl)-4(1H)-cinnolinone N-oxides | |
JPS62198684A (ja) | 3−(1H−テトラゾ−ル−5− イル) チエノ〔2,3−d〕 ピリミジン−4(3H)−オン類 | |
PL100058B1 (pl) | Sposob wytwarzania nowych n-/6-acyloksybenzotiazolilo-2/-n-fenylomocznikow |